Cannabis Law Report

NOVEMBER 22, 2019

MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada. “Patients will benefit from cGMP-quality therapies in an accessible and efficient format.”. . Most recently the FDA awarded MMJ International Holdings ?

DEA

Cannabis Law Report

AUGUST 27, 2021

ACS Laboratory Will Grant its Safety Seal to Any Product Testing Beyond the Minimum for a Full Panel of Tests. ACS Laboratory’s Tested Safe Certified Safety Seal is a physical symbol that products passed the strictest testing guidelines in the U.S. BOCA RATON, Fla. , Aug. BOCA RATON, Fla. , Aug.

Cannabinoids

Cannabis Law Report

JUNE 10, 2021

(OTC: CURR), a vertically integrated drug delivery and product development company, announced today that it has signed a partnership agreement with Biopharmaceutical Research Company , (BRC), an active Drug Enforcement Administration (DEA) license holder, to produce federally-compliant cannabis-based medical products.

Pharmaceutical

Medical Marijuana Program Connection

MAY 2, 2024

The US Drug Enforcement Agency (DEA) is moving forward with plans to move marijuana from a Schedule I to a Schedule III controlled substance under the Controlled Substance Act (CSA), the US Department of Justice officials announced this week. First reported by the Associated Press and since confirmed by Medscape. Read More

DEA

Freedom Leaf

OCTOBER 15, 2018

On September 28, the DEA designated Epidiolex —a plant-based CBD pharmaceutical manufactured by the UK-based GW Pharmaceuticals—a Schedule V drug in the government’s list of controlled substances. schedules were created by the Controlled Substances Act (CSA) in 1970 and are interpreted and enforced by the DEA.

DEA

Veriheal

APRIL 11, 2022

You don’t take that opium poppy and ask a patient to rub it on their lip for morphine. We know that the plant has powerful potential medical effects, but it clearly needs more refinement, more research and more data,” stated Groff, who envisions a future where patients can easily access ailment-targeted cannabis meds.

Pharmaceutical

Cannabis Law Report

JUNE 12, 2021

MONTEREY, CA – Biopharmaceutical Research Company (BRC), an active Drug Enforcement Administration (DEA) license holder, and CURE Pharmaceutical Holding Corp. CURE has established itself as a leader in the oral application of cannabis-derived treatments, and we know we’ll be able to bring a lot of value to patients together.”.

DEA

The Cannigma

MAY 16, 2025

The successes of cannabis businesses are now a part of the mainstream conversation and considered big business, while the rights and protections for medical cannabis patients have been sidelined. So while a cannabis business can join their local chamber of commerce, a patient in hospice can be denied access to medical cannabis.

Policy

Veriheal

JUNE 23, 2022

Outdated practices and a patchwork of laws create a legal minefield for medical patients to navigate in particular. A great example of this can be found in Pennsylvania with the case of medical cannabis patient Patrick Murphy. MMJ Patients Criminalized Despite Legality. You can read the entirety of the case appeal here.

Consumption

The Cannigma

MAY 6, 2021

When it comes to safety, the two main factors to consider are production (standards and regulation) and research. Even if you were able to verify the production standards and active ingredients, there’s just not enough scientific literature to support the safety of consuming high levels of delta-8-THC in the long term.

THC

Cannabis Law Report

JUNE 15, 2021

Drug Enforcement Administration-McAlester Resident Office and DEA Denver. The investigation was initiated by the DEA Denver office’s “Front Range Task Force” after a Chinese money laundering organization was identified that sold black market marijuana “to fund and further their criminal activities,” the sheriff office stated.

DEA

Cannabis Law Report

JULY 9, 2021

Patients would participate in therapy sessions to prepare for the use of psychedelics, after which the substances would be administered under the guidance and supervision of trained medical professionals. Right to Try laws permit patients with serious or life-threatening diseases to access drugs that do not yet have government approval.

Law

Cannabis Law Report

JULY 1, 2021

Mason Marks: The project’s goal is to promote safety, innovation, equity, and accessibility in emerging psychedelics industries. Things have changed a little in the past twenty years, when the DEA gave some researchers permission to study limited amounts of certain psychedelics. POPLAR will publish original law and policy research.

Law

Sensi Seeds

NOVEMBER 28, 2018

Then, a blog post circulated online, notifying the industry that Spain’s food and safety authority, AECOSAN, had updated its legislation to prohibit the sale and distribution of products containing CBD being sold as food supplements. In August 2018, reports of shops being raided and CBD product confiscated began to circulate on Twitter.

CBD

Cannabis Law Report

OCTOBER 31, 2019

“The fact is, it is still too easy and lucrative for these medical growers to jeopardize their patients by diverting patient controlled marijuana products to the illegal market.”. However, the Oregon Legislature authorized the OLCC beginning July 1, 2018 to inspect OMMP grow sites with three or more patients (13 or more plants.)

Oil

Cannabis Law Report

APRIL 8, 2022

Later that year, Doblin sued the DEA for the first time. The FDA formally decided to open the door to psychedelic research in human participants, and later accepted MAPS’ Phase 1 MDMA safety and tolerance study protocol. submitted his first DEA application to manufacture marijuana for use in medical research.

Clinical Trials

Medicinal Genomics

FEBRUARY 8, 2023

Set at the beautiful Marriot Marco Island Resort, CannMed 23 provides an immersive forum where cannabis researchers, physicians, patients, entrepreneurs, and investors can collaborate and share their latest innovations and insights. The CannMed 23 Innovation and Investment Summit is a cannabis industry event like no other.

Wellness and Beauty

SpeedWeed

MARCH 21, 2021

Typically, patients may experience some of the same analgesic and antiemetic effects as Delta-9,” he adds. But there are potential safety concerns. Delta-8 isn’t mentioned by name in the 2018 Farm Bill, the DEA’s IFR or the Controlled Substances Act. A case addressing the DEA’s IFR is currently moving through the U.S.

THC

SpeedWeed

MARCH 17, 2021

Typically, patients may experience some of the same analgesic and antiemetic effects as Delta-9,” he adds. But there are potential safety concerns. Delta-8 isn’t mentioned by name in the 2018 Farm Bill, the DEA’s IFR or the Controlled Substances Act. A case addressing the DEA’s IFR is currently moving through the U.S.

DEA

Cannabis Law Report

APRIL 21, 2022

Publication of this process establishes “prior art,” contributing to MAPS’ patient access strategy by making intellectual property public . 30,000 patient doses) of MDMA in a four-step process beginning with a non-controlled starting material. The safety and efficacy of MDMA-assisted therapy is currently under investigation.

Clinical Trials

Cannabis Law Report

SEPTEMBER 23, 2021

Tracking recent data from within the last year (following the publication of the DEA Interim Final Rule which added confusion to the delta-8 legality question), more than a dozen hospital or emergency room visits and hundreds of calls to poison control were reported. Delta-8 THC products should be kept out of the reach of children and pets.

THC

Cannabis Law Report

MAY 24, 2022

Defendant and respondent Oakland Cannabis Buyers’ Cooperative created a medical dispensary that would serve eligible patients. Substances considered to pose the greatest risk to the public health and safety are subject to the most stringent controls and sanctions.

DEA

PrestoDoctor

JANUARY 14, 2020

Other states have a list of conditions that the patients must meet to get an MMJ. government Tribal identification card approved by the Oklahoma Department of Public Safety for identification. You must have an Adult Patient Physician Recommendation Form dated within 30 days of the application. Will I Be Put on a List?

Marijuana

PrestoDoctor

JANUARY 14, 2020

Other states have a list of conditions that the patients must meet to get an MMJ. government Tribal identification card approved by the Oklahoma Department of Public Safety for identification. You must have an Adult Patient Physician Recommendation Form dated within 30 days of the application. Will I Be Put on a List?

Marijuana

PrestoDoctor

FEBRUARY 6, 2023

Other states have a list of qualifying conditions that the patients must meet to get an MMJ. Finally, you will complete the application and get charged for your appointment (patients only pay if approved!). You must also have an Adult Patient Physician Recommendation Form dated within 30 days of the application.

Marijuana

SpeedWeed

MARCH 21, 2021

Typically, patients may experience some of the same analgesic and antiemetic effects as Delta-9,” he adds. But there are potential safety concerns. Delta-8 isn’t mentioned by name in the 2018 Farm Bill, the DEA’s IFR or the Controlled Substances Act. A case addressing the DEA’s IFR is currently moving through the U.S.

Research and Development

PrestoDoctor

JULY 16, 2019

In their most recent federal lawsuit, CCA attorneys are representing 5 different plaintiffs, all of whom demonstrate that maintaining cannabis as a schedule 1 drug is unconstitutional and a risk to their health as patients. According to plaintiff José Belén, “the DEA was told to act with ‘great dispatch’ and with ‘all deliberate speed”.

Policy

PrestoDoctor

JULY 16, 2019

In their most recent federal lawsuit, CCA attorneys are representing 5 different plaintiffs, all of whom demonstrate that maintaining cannabis as a schedule 1 drug is unconstitutional and a risk to their health as patients. According to plaintiff José Belén, “the DEA was told to act with ‘great dispatch’ and with ‘all deliberate speed”.

Policy

The Cannigma

JULY 3, 2023

They found that it could be used in sessions to promote trust and safety, helping patients to open up and process traumatic experiences. 12 From a safety perspective, there are concerns about mixing drugs increasing chances of addiction across the board, and of course unpredictable, and potentially dangerous impairment.

Research and Development

Cannabis Law Report

SEPTEMBER 23, 2019

Marijuana and related substance misuse are complex issues impacting family medicine, patient health, and public health. Barriers to facilitating both clinical and public health research regarding marijuana is detrimental to treating patients and the health of the public. Executive Summary. Relevant AAFP Policy. Call to Action.

Cannabinoids

Cannabis Law Report

NOVEMBER 11, 2021

As detailed in our previous post , the MRTA required the CCB to “issue rules and regulations governing the home cultivation of cannabis by certified [medical marijuana] patients. no later than six months after the effective date of the MRTA.”

Programs

Cannabis Law Report

JULY 14, 2021

Importantly, the legislation also ends discrimination in federal public benefits for medical marijuana patients and adult use consumers. Additionally, revenue generated by federal taxes will support restorative justice and public health and safety research. Senators Cory Booker, D-N.J., Ron Wyden, D-Ore., and Chuck Schumer, D-N.Y.,

Legislation

Cannabis Law Report

APRIL 13, 2022

.” Yaron Conforti , CEO and Co-Founder, Novamind, said, “This transaction offers significant value for Novamind’s shareholders and provides compelling new opportunities for our employees, patients and research partners. The combination of Novamind’s network of mental health clinics and research sites in the U.S.

Clinical Trials

Canna Law Blog

MAY 7, 2020

At the same time, because of the federal illegality of cannabis, the federal government has routinely denied third party requests for further research in regards to its potential medical benefits, among other health and safety impacts. As of December 2019, there are only two patients on the coveted list and no new entrants are permitted.

DEA

The Cannigma

MAY 15, 2023

Ketamine has a long safety record as an anesthetic since the 1980s, and it has also been successfully used “off-label” for over a decade to treat conditions such as anxiety, depression, OCD, and PTSD, among others. Patients may want to seek assistance from a certified professional prior to embarking on treatment.

Therapy

Canna Law Blog

SEPTEMBER 6, 2023

Many people in the cannabis industry are convinced that this HHS recommendation to the Drug Enforcement Administration (DEA) means that the DEA will undertake this rescheduling (and fairly quickly, too–which would be a huge departure from its refusal to reschedule back in 2016). Just my two cents; feel free to disagree.

Research and Development

Veriheal

AUGUST 31, 2020

Essay Summary: Nishtha wants to further research into THC treatment for patients suffering from neurodegenerative diseases like Alzheimer’s and epilepsy , both of which cause neuron death. Essay: “Can Cannabis Improve Patient Experience Post-Surgery?” . Program between St. Vaibhav Duggal . School: Texas A&M University .

Research and Development